HKSE - Delayed Quote HKD

JUNSHI BIO (1877.HK)

14.120
-0.380
(-2.62%)
At close: 4:08:31 PM GMT+8
Loading Chart for 1877.HK
  • Previous Close 14.500
  • Open 14.520
  • Bid 14.120 x --
  • Ask 14.160 x --
  • Day's Range 14.100 - 14.880
  • 52 Week Range 9.720 - 21.700
  • Volume 2,125,600
  • Avg. Volume 2,609,232
  • Market Cap (intraday) 26.08B
  • Beta (5Y Monthly) 0.63
  • PE Ratio (TTM) --
  • EPS (TTM) -1.400
  • Earnings Date Mar 27, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.78

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

www.junshipharma.com

2,578

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1877.HK

View More

Performance Overview: 1877.HK

Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

1877.HK
21.51%
HANG SENG INDEX (^HSI)
15.20%

1-Year Return

1877.HK
11.89%
HANG SENG INDEX (^HSI)
20.89%

3-Year Return

1877.HK
77.76%
HANG SENG INDEX (^HSI)
16.13%

5-Year Return

1877.HK
63.98%
HANG SENG INDEX (^HSI)
4.43%

Compare To: 1877.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1877.HK

View More

Valuation Measures

As of 5/12/2025
  • Market Cap

    26.79B

  • Enterprise Value

    26.80B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.82

  • Price/Book (mrq)

    2.26

  • Enterprise Value/Revenue

    12.80

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -59.68%

  • Return on Assets (ttm)

    -7.16%

  • Return on Equity (ttm)

    -21.15%

  • Revenue (ttm)

    2.07B

  • Net Income Avi to Common (ttm)

    -1.23B

  • Diluted EPS (ttm)

    -1.400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.02B

  • Total Debt/Equity (mrq)

    49.07%

  • Levered Free Cash Flow (ttm)

    -760.21M

Research Analysis: 1877.HK

View More

People Also Watch